Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma

Peter Mclaughlin, William S. Velasquez, John R. Redman, W. k.Alfred Yung, Fredrick B. Hagemeister, Maria A. Rodriguez, Fernando Cabanillas

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Ten Patients with parenchymal CNS lymphoma received combination che-motherapy with dexamethasone, high-dose cytarabine, and cisplatin(DHAP), and additional therapy according toclinical circumstances. Two of four patients with primary CNS lym-phoma achieved and remain in completeremission (CR). Four of six patients with CNS lymphoma at relapse also achieved CR. DHAP is activeagainst CNS lymphoma. Flurther trials with DHAP, Particularly in conjunction with other treatment modalities, are warranted. [J Natl Cancer Inst 1988;80:1408-1412].

Original languageEnglish (US)
Pages (from-to)1408-1412
Number of pages5
JournalJournal of the National Cancer Institute
Volume80
Issue number17
DOIs
StatePublished - Feb 2 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma'. Together they form a unique fingerprint.

Cite this